Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814702 | 1.00 | DGAT2 (0.48) | DGAT2TACR3USP30SSTR3HDAC4 | |
| SCHEMBL13801614 | 0.93 | TACR2 (0.45) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13801636 | 0.93 | TACR2 (0.45) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13814678 | 0.93 | TACR2 (0.45) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13814586 | 0.93 | TACR2 (0.45) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13801256 | 0.93 | TACR2 (0.45) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13801254 | 0.92 | KMT2A (0.51) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13814658 | 0.92 | KMT2A (0.51) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13801251 | 0.91 | TACR2 (0.46) | USP30HDAC4HDAC6SPTLC2PDE4B | |
| SCHEMBL13814637 | 0.91 | TACR2 (0.46) | USP30HDAC4HDAC6SPTLC2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | DGAT2 4099/4885TACR3 97/4885USP30 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.